Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT.

  title={Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT.},
  author={Sam Barratt and Julia A. Bielicki and David Dunn and Saul N. Faust and Adam Finn and Lynda Harper and Pauline Jackson and Mark David Lyttle and Colin V. E. Powell and Louise Rogers and Damian Roland and Wolfgang St{\"o}hr and Kate Sturgeon and Elizabeth J. Vitale and Mandy Wan and Diana M. Gibb and Mike Sharland},
  journal={Health technology assessment},
  volume={25 60},
BACKGROUND Data are limited regarding the optimal dose and duration of amoxicillin treatment for community-acquired pneumonia in children. OBJECTIVES To determine the efficacy, safety and impact on antimicrobial resistance of shorter (3-day) and longer (7-day) treatment with amoxicillin at both a lower and a higher dose at hospital discharge in children with uncomplicated community-acquired pneumonia. DESIGN A multicentre randomised double-blind 2 × 2 factorial non-inferiority trial in… 

Treatment of the most common respiratory infections in children

The use of antibiotics and corticosteroids is indicated in selected cases with a severe clinical picture and the choice of antibiotic depends on the clinical condition, presumed causative agent, and local epidemiologic circumstances.

Amoxicillin for childhood pneumonia: 3 days versus 7 days

  • Medicine
    Drug and Therapeutics Bulletin
  • 2022
Amoxicillin duration and dose for community acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT.



Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT)

The CAP-IT trial aims to determine the optimal amoxicillin treatment strategies for CAP in young children in relation to efficacy and AMR, and key messages will be constructed in partnership with families, and social media will be used in their dissemination.

Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial

Treatment with oral amoxicillin for three days was as effective as for five days in children with non-severe pneumonia, and was associated with isolation of respiratory syncytial virus.

Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial.

Oral amoxicillin (50 mg/kg/day) twice daily is as efficacious as thrice daily in patients with non-severe childhood pneumonia, and compliance could be enhanced if two daily doses are employed.

Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial

Oral amoxicillin is effective for most children admitted to hospital with pneumonia (all but those with the most severe disease who were excluded from this study) and will spare children and their families the trauma and pain of cannulation, and children will spend less time in hospital.

Amoxicillin 3 vs 5 days for chest-indrawing pneumonia in Malawian children

In HIV-uninfected African children, 3 days of amoxicillin treatment for chestindrawing pneumonia was non-inferior to 5 days, and antibiotictreatment guidelines applicable to similar pediatric populations are recommended.

Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months

In HIV-uninfected children aged 2 to 59 months in a malaria-endemic region of Malawi, placebo treatment of nonsevere fast-breathing pneumonia was significantly inferior to treatment with amoxicillin.

Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children.

Among children 6 to 23 months of age with acute otitis media, reduced-duration antimicrobial treatment resulted in less favorable outcomes than standard-duration treatment; in addition, neither the rate of adverse events nor the rates of emergence of antimicrobial resistance was lower with the shorter regimen.

Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.

  • J. BradleyG. Mccracken
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
Patients- or parent-reported outcomes represent an option for appropriate, defined clinical trial outcomes for pediatric CAP, because the disease in children has a relatively short and potentially self-resolving clinical course.